Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Understanding real-world microbiological outcomes will guide long-term CFTR modulator use in CF, says GlobalData

At the 2025 European Respiratory Society (ERS) International Congress in Amsterdam, researchers from Dalhousie University and the University of Toronto presented findings from a comprehensive, registry-based analysis examining the long-term clinical and microbiological impacts of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy. The study, spanning data from 2019-2023 across Canadian and US cystic fibrosis […]
Read more

Anbenitamab to gain competitive edge as first bispecific mAb in HER-positive gastric cancer market in China, says GlobalData

China’s National Medical Products Administration (NMPA) has recently accepted the New Drug Application (NDA) of Alphamab Oncology’s KN026 (anbenitamab). If approved, KN026 is expected to become the first bispecific monoclonal antibody (mAb) targeting HER2-positive gastric or gastroesophageal (GEJ) carcinoma and evolve as a potential treatment option in the gastric cancer landscape in China, says GlobalData, […]
Read more

Breakthroughs in idiopathic pulmonary fibrosis may lead to first approval in years, says GlobalData

After years of limited progress, new treatments for idiopathic pulmonary fibrosis (IPF) are moving closer to approval. Boehringer Ingelheim’s nerandomilast has shown strong Phase III results and could secure approval later in 2025, while United Therapeutics’ inhaled treprostinil advances in late-stage trials, signaling a potential breakthrough for patients facing this debilitating lung disease, says GlobalData, […]
Read more

FDA ends HAE drought with record approvals in 2025, reveals GlobalData

After four years of inactivity, the FDA approved three novel products for hereditary angioedema (HAE) in 2025. This bumper year increased the total number of marketed innovator drugs in the US to 11, introducing new mechanisms and modalities that broaden the treatment strategies available to patients, according to GlobalData, a leading data and analytics company. […]
Read more

Pozelimab and cemdisiran combination holds potential to challenge existing complement inhibitors in MG market, says GlobalData

Regeneron recently announced exciting results from a Phase III clinical trial called NIMBLE, evaluating the efficacy and safety of pozelimab + cemdisiran combination therapy and cemdisiran monotherapy for adult patients living with generalized myasthenia gravis (gMG). The results showed that both cemdisiran monotherapy and pozelimab + cemdisiran combination therapy met their primary endpoints, displaying a […]
Read more

World Sepsis Day 2025: Improved awareness, faster diagnosis, and investment in novel therapeutics key to tackle huge healthcare burden, says GlobalData

World Sepsis Day, which takes place annually on September 13, aims to raise awareness and understanding of this life-threatening condition. World Sepsis Day 2025 also marks one year since the launch of the 2030 Global Agenda for Sepsis by the Global Sepsis Alliance. This strategy aims to reduce the global incidence of sepsis by at […]
Read more

Four drugs in race for first bispecific ADC approval, reveals GlobalData

Bispecific (bs) antibody drug conjugates (ADCs) are an emerging therapeutic approach that presents advantages over traditional ADCs. With 84% of bsADCs in the preclinical or discovery stages, the pipeline is still nascent. However, with four candidates in Phase III, the race for the first approval in this novel landscape is underway, according to GlobalData, a […]
Read more

Semaglutide patent cliff to present substantial opportunity for companies in the Chinese generics market, says GlobalData

Semaglutide, marketed as Ozempic for diabetes and Wegovy for obesity, ranked among the top-selling drugs globally in 2024. While patents protect the drug until 2031-2032 in seven major markets, China’s patent expires much earlier, in March 2026. Chinese pharmaceutical companies are aggressively preparing their manufacturing capabilities and regulatory approvals to capitalize on this multi-billion-dollar market […]
Read more

FDA acceptance of VCTE as trial endpoint can accelerate MASH drug development, says GlobalData

Following the news that the US FDA has accepted Echosens’ letter of intent to qualify liver stiffness measurement (LSM) by vibration-controlled transient elastography (VCTE) as a reasonably likely surrogate endpoint for metabolic dysfunction-associated steatohepatitis (MASH) trials with moderate-to-advanced fibrosis; Jay Patel, Senior Pharma Analyst at GlobalData, a leading data and analytics company, comments: “The announcement […]
Read more

US eosinophilic esophagitis market to reach $1.19 billion by 2030, forecasts GlobalData

The US eosinophilic esophagitis (EoE) market is projected to grow from $202 million in 2020 to $1.19 billion in 2030, registering a compound annual growth rate (CAGR) of 19.4%, driven by the transition from off-label therapies to FDA-approved, patient-friendly options such as Sanofi/Regeneron’s Dupixent (dupilumab), Takeda’s Eohilia (budesonide oral suspension), and Ellodi Pharmaceuticals’ late-stage pipeline […]
Read more

CRISPR-based therapeutics hold potential to combat AMR and cure chronic viral infections, says GlobalData

Clustered regularly interspaced short palindromic repeats (CRISPR)-based therapeutics are rapidly gaining traction for the management of infectious diseases. Programs targeting pathogens such as the human immunodeficiency virus (HIV), herpes simplex virus (HSV), and drug-resistant Escherichia coli (E. coli) are advancing in the clinic, signaling a transformative shift in the infectious disease space. CRISPR-based therapeutics show […]
Read more

Insmed’s pivotal win in bronchiectasis highlights potential of DPP-1 inhibitor in growing respiratory field, says GlobalData

Following the US FDA approval of Insmed’s Brinsupri for treatment of non-cystic fibrosis bronchiectasis (NCFB): Vinie Varkey, Pharma Analyst at GlobalData, a leading data and analytics company, offers her view: “As the first-to-market therapy, Brinsupri (brensocatib) addresses the top unmet need for NCFB: an approved therapy that can reduce exacerbations and slow down the disease […]
Read more

AI improving idiopathic pulmonary fibrosis care, says GlobalData

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease characterized by the accumulation of scar tissue in the lungs, leading to respiratory failure and significantly impacting patients’ quality of life. Recent advancements in AI have emerged as a promising tool that can contribute to the management of IPF. AI algorithms that employ machine learning and […]
Read more
1 … 6 7 8 9 10 … 110